Stephens Inc. AR boosted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 60.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 37,011 shares of the company’s stock after buying an additional 13,898 shares during the quarter. Stephens Inc. AR’s holdings in Teva Pharmaceutical Industries Limited were worth $1,229,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Oarsman Capital Inc. grew its position in Teva Pharmaceutical Industries Limited by 11.8% in the second quarter. Oarsman Capital Inc. now owns 60,892 shares of the company’s stock worth $2,023,000 after buying an additional 6,432 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Teva Pharmaceutical Industries Limited by 5.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 22,957 shares of the company’s stock worth $762,000 after buying an additional 1,279 shares during the last quarter. Nations Financial Group Inc. IA ADV acquired a new position in Teva Pharmaceutical Industries Limited in the second quarter worth approximately $358,000. Financial Counselors Inc. grew its position in Teva Pharmaceutical Industries Limited by 5.7% in the second quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock worth $4,671,000 after buying an additional 7,571 shares during the last quarter. Finally, Alliancebernstein L.P. grew its position in Teva Pharmaceutical Industries Limited by 32.3% in the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock worth $378,688,000 after buying an additional 2,782,257 shares during the last quarter. Hedge funds and other institutional investors own 56.87% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/16/stephens-inc-ar-acquires-13898-shares-of-teva-pharmaceutical-industries-limited-teva.html.

Several research analysts have issued reports on the stock. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, September 11th. Jefferies Group LLC restated a “hold” rating and issued a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Maxim Group restated a “hold” rating and issued a $15.50 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday. Deutsche Bank AG restated a “buy” rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Finally, UBS AG restated a “neutral” rating and issued a $19.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $31.42.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 18.10 on Friday. The company has a 50 day moving average of $19.00 and a 200 day moving average of $28.55. The firm’s market cap is $18.39 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $51.61.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period last year, the business posted $1.25 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were given a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -15.36%.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.